We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Roche's partner AC Immune said Tuesday that the former has decided to initiate a second Phase III study of the experimental Alzheimer's disease therapy crenezumab. AC Immune noted that the CREAD2 trial will enrol 750 patients with prodromal or mild Alzhei